EP Patent

EP0934341A1 — Inclusion complexes of beta-2-andrenergics for oral mucosal delivery

Assigned to Farmac Nederland BV · Expires 1999-08-11 · 27y expired

What this patent protects

A pharmaceutical composition for oral mucosal delivery comprises an active ingredient, an inclusion complex of (a) a selective β2-adrenergic agonist or a pharmaceutically acceptable salt thereof such as salbutamol, and (b) an unsubstituted or substituted beta- or gamma-cyclodextr…

USPTO Abstract

A pharmaceutical composition for oral mucosal delivery comprises an active ingredient, an inclusion complex of (a) a selective β2-adrenergic agonist or a pharmaceutically acceptable salt thereof such as salbutamol, and (b) an unsubstituted or substituted beta- or gamma-cyclodextrin, and a pharmaceutically acceptable carrier for oral mucosal delivery. The pharmaceutical composition is of use in the treatment of reversible obstructive airways diseases such as asthma.

Drugs covered by this patent

Patent Metadata

Patent number
EP0934341A1
Jurisdiction
EP
Classification
—
Expires
1999-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Farmac Nederland BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.